- After tumbling some 20% late last week on news that the vintafolide monotherapy arm in TARGET was (in the opinion of the DSMB) not likely to be declared superior to docetaxel in terms of PFS, Endocyte (ECYT +10.9%) recoups some of its losses as Phase 2 data shows vintafolide plus PLD resulted in a median PFS of 5 months in women with platinum-resistant ovarian cancer versus 2.7 months for the PLD alone group.
- The Hazard Ratio was 0.63.
- The results were published in the Journal of Clinical Oncology. (PR)
Endocyte rallies as vintafolide PRECEDENT results published
From other sites
at Zacks.com (Mar 6, 2015)
at Zacks.com (Feb 20, 2015)
at CNBC.com (Sep 29, 2014)
at CNBC.com (Jun 18, 2014)
at CNBC.com (Jun 17, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs